Lark L A Coffey

Lark L A Coffey

Associate Professor

Pathology, Microbiology & Immunology

Office
1 Shields Ave, Davis, CA 95616

Licenses
UC Davis Biomedical and Engineering Entrepreneurship Academy Graduate
Education
2000, B.S., University of the South, Sewanee, Tennessee
2005, Ph.D., University of Texas Medical Branch, Galveston, Texas
2006, post-doctoral fellowship, Institut Pasteur, Paris, France
2011, post-doctoral fellowship, Blood Systems Research Institute/University of California San Francisco, California, San Francisco, California
2013, Assistant Professor, University of California, Davis, Davis, California
Active Research Grants
Principal Investigator, Engineering high fidelity mutations to increase safety of live-attenuated alphavirus vaccines , (Principal Investigator), NIH NIAID
Principal Investigator, Centers for Research in Emerging Infectious Disease, (Principal Investigator), NIH NIAID
Co-Investigator, MMRRC COVID-19 variant testing in humanized mouse models, Kent Lloyd (Principal Investigator), NIH Office of the Director
Co-Investigator, Pacific Southwest Regional Center of Excellence for Vector-Borne Disease Research at the University of California, Chris Barker (Principal Investigator), Centers for Disease Control Regional Centers of Excellence
Co-Investigator, Impacts of rapid landscape change and biodiversity on virus host specificity, Christine Kreuder Johnson (Principal Investigator), NSF/ Ecology and Evolution of Infectious Diseases
Co-Investigator, Cognitive, affective, and social development following fetal Zika virus infection of rhesus macaques. , Eliza Bliss-Moreau (Principal Investigator), NIH NICHD
Co-Investigator, Treatments for Zika virus infection macaques, Koen KA Van Rompay (Principal Investigator), Open Philanthropy Project
Principal Investigator, Small animal models of SARS-CoV-2, (Principal Investigator), UC Davis Office of Research
Co-Investigator, Enhancement of existing ABSL3 facilities to accommodate expanded mouse validation and phenotyping, Kent Lloyd (Principal Investigator), NIH Office of Research Infrastructure Programs
Principal Investigator, Antivirals drugs for SARS-CoV-2, (Principal Investigator), Open Philanthropy
Co-Investigator, Dual Anti-inflammatory and Antiviral Strategy to Combat COVID-19, Dominik Haudenschild (Principal Investigator), DOD US Army CDMRP
Principal Investigator, Evaluating mosquito excreta as an early warning system for arbovirus surveillance in remote locations, (Principal Investigator), Coachella Valley (California) Mosquito and Vector Control District (LL Coffey)
Honors and Awards
2021 UC Davis Chancellor’s Fellow
Most Recent Five Book Chapters
2016 Coffey LL: The Nature of Viruses, MacLachlan, NJ, Dubai, EJ, (ed), Fenner’s Veterinary Virology, London. 13-16.
2016 Coffey LL, Weaver SC, Forrester N: Alphavirus Evolution, , Alphaviruses: Molecular Biology, Pathogenesis and Host Interactions, . 21-26.
2016 Forrester NL, Gutierrez S, Coffey LL: The Evolution and Transmission of Vector-Borne Viruses, Weaver, Denison, Roossinck, Vignuzzi, (ed), Virus Evolution: Current Research and Future Directions, . 61-100.
2015 Tsetsarkin K, Coffey LL, Weaver SC: Interaction of Chikungunya virus with the mosquito vector, , Chikungunya Virus, . 99-126.
2008 Coffey LL: Togaviruses not associated with human disease, Mahy B, Van Regenmortel M, (ed), Encyclopedia of Virology, 3rd Edition, Oxford. 91-6.
Research Focus
Mosquito-borne virus transmission dynamics, evolution, and emergence Viral genetic mechanisms of emergence focusing on modified virus-host interactions, with a goal of interrupting transmission to reduce human and animal disease.
Specialty Focus
Transmission dynamics and genetics of mosquito-borne alpha- and flaviviruses, RNA virus evolution, SARS-CoV-2 small animal models and countermeasure testing.